1033602-66-2

Upstream product

• 40530-18-5 5-bromo-2-hydroxybenzonitrile 
• 107-30-2 chloromethyl methyl ether 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 1033602-67-3 3-cyano-4-methoxymethoxyphenylboronic acid 
• 1160219-20-4 2-(methoxymethoxy)-5-(6-methylpyridin-2-ylethynyl)benzonitrile 
• 1227700-93-7 2-methoxymethoxy-5-(2-methylquinolin-7-yl)benzonitrile 
• 1033602-72-0 ethyl 2-(3-cyano-4-hydroxyphenyl)nicotinate hydrochloride 
• 1033602-15-1 ethyl 2-{4-[2-(2-chlorophenyl)ethoxy]-3-cyanophenyl}nicotinate 
• 1033601-24-9 C₂₄H₂₂N₂O₄ 
• 1033602-76-4 ethyl 2-[4-(3-chloropropoxy)-3-cyanophenyl]nicotinate 
• 1033600-98-4 ethyl 2-(3-cyano-4-isobutoxyphenyl)-nicotinate 
• 1033602-68-4 ethyl 2-(3-cyano-4-methoxymethoxyphenyl)nicotinate 
• 1033600-97-3 ethyl 2-(3-cyano-4-methoxyphenyl)-nicotinate 
• 1033601-47-6 2-(3-Cyano-4-methoxyphenyl)nicotinic acid 

Relevant academic research and scientific papers

Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5

The metabotropic glutamate receptor subtype 5 (mGluR5) has been implicated in numerous neuropsychiatric disorders including addiction. We have discovered that the rigid diaryl alkyne template, derived from the potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), can serve to guide the design of novel quinoline analogues and pharmacophore optimization has resulted in potent mGluR5 noncompetitive antagonists (EC50 range 60-100 nM) in the quinoline series.

Structure-activity relationships comparing N-(6-methylpyridin-yl)- substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists

The metabotropic glutamate receptor subtype 5 (mGluR5) has been implicated in anxiety, depression, pain, mental retardation, and addiction. The potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP, 1) has been a critically important tool used to further elucidate the role of mGluR5 in these CNS disorders. In an effort to provide novel and structurally diverse selective mGluR5 antagonists, we previously described a set of analogues with moderate activity wherein the alkyne bond was replaced with an amide group. In the present report, extended series of both amide and alkyne-based ligands were synthesized. MGluR5 binding and functional data were obtained that identified (1) several novel alkynes with comparable affinities to 1 at mGluR5 (e.g., 10 and 20-23), but (2) most structural variations to the amide template were not well tolerated, although a few potent amides were discovered (e.g., 55 and 56). Several of these novel analogues show drug-like physical properties (e.g., cLogP range = 2-5) that support their use for in vivo investigation into the role of mGluR5 in CNS disorders.

2-PHENYLNICOTINIC ACID DERIVATIVE

The present invention is to provide the compounds useful as a treating or preventing agent for gout and hyperuricemia which are 2-phenylnicotinic acid derivatives having a uric acid lowering action due to an excellent xanthine oxidase inhibitory action. Since the 2-phenylnicotinic acid derivatives of the present invention exhibit a uric acid lowering action due to an excellent xanthine oxidase inhibitory action and also hypolipemic action, their utility is very high as a treating or preventive agent for gout and hyperuricemia which are often accompanied by hyperlipemia as a complication.